FOSTER CITY, Calif. and HANGZHOU, ZHEJIANG, CHINA, Mar 4, 2021 - (ACN Newswire) - Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the first patient has been successfully enrolled into a Phase 1 clinical trial of APL-106...